Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

计划入组 68 人 · 首次发布于 2020 年 11 月 9 日

Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer

计划入组 55 人 · 首次发布于 2024 年 11 月 7 日

FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy

计划入组 50 人 · 首次发布于 2022 年 9 月 9 日

PD-L1 checkpoint inhibitor gene therapy (Affimer/gtGTU vector) (Avacta/FIT Biotech)

Anti-PD-1-GITR-L

Anti-PDL1 chimeric switch receptor modified T-cell therapy (Marino Biotechnology)

PD-RX Pharmaceuticals, Inc.

United States

NHI-1

United States

ATI Physical Therapy

United States

BMS-986253 Fails to Improve Outcomes in Advanced Melanoma Post-PD-1/L1 Therapy

Combination Immunotherapies Show Promise in Pancreatic Cancer Treatment

BeyondSpring's Plinabulin Shows Consistent Survival Benefit in EGFR Wild-Type NSCLC After Anti-PD-(L)1 Failure